A. Tripodi

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A Tripodi, A. Tripodi, Armando Tripodi
Publication record
458 papers · 22,367 citations · H-index 70

PAPERS

Bilirubin color interference on prothrombin time and activated partial thromboplastin time tests assessed in patients with liver disease
20230 citationsauthor #7
The role of anticoagulation clinics needs to be reassessed to include follow up of patients on direct oral anticoagulants.
20231 citationsauthor #1
"The ISTH SSC subcommittee on hemostatic management of patients with liver disease: goals, ambitions, and call for collaboration": comment.
20231 citationsauthor #1
The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease.
20237 citationsauthor #3
Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients
20233 citationsauthor #14
Laboratory investigation and diagnosis of thrombotic thrombocytopenic purpura
20235 citationsauthor #2
Is non-alcoholic fatty liver disease a prothrombotic risk factor?
20230 citationsauthor #4
Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients
202310 citationsauthor #1
The link between inflammation and hemostasis in endometriosis: a call for research
20238 citationsauthor #2
Hemophilia patients: are they naturally anticoagulated?
20232 citationsauthor #1
“Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH”: Reply
202215 citationsauthor #6
The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time.
20220 citationsauthor #6
Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia
202215 citationsauthor #13
Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences
202224 citationsauthor #1
Hemostasis from Bench to Bedside: The History of Three Successful Stories of Translational Medicine
20222 citationsauthor #1
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection in plasma containing argatroban
20221 citationsauthor #4
Patients with chronic liver disease. Are they naturally anticoagulated?
20222 citationsauthor #1
Procoagulant imbalance in male hypogonadism and effect of short-term testosterone replacement therapy
20220 citationsauthor #9
Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding.
202229 citationsauthor #3
Interplay between coagulation and determinants of liver disease in patients with metabolic dysfunction
202219 citationsauthor #2
Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH
202228 citationsauthor #6
Cirrhosis. What are all those factor VIII and protein C for?
20221 citationsauthor #1
Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study
20224 citationsauthor #14
Whole blood platelet aggregation measurement by Multiplate™: potential diagnostic inaccuracy of correcting the results for the sample platelet count
202211 citationsauthor #3
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction
20223 citationsauthor #2
Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges
20228 citationsauthor #3
Thromboplastin calibration revisited to look for possible revision of the World Health Organization recommendations.
20224 citationsauthor #1
Assessment of Platelet Thrombus Formation under Flow Conditions in Adult Patients with COVID-19: An Observational Study
202110 citationsauthor #15
Anti-TNF-α Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases.
202110 citationsauthor #1
Relationship between thrombin generation parameters and prothrombin fragment 1 + 2 plasma levels
20216 citationsauthor #10
The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease
2021113 citationsauthor #7
Coagulation balance and liver damage in non-cirrhotic patients with chronic hepatitis C after eradication by Direct-acting Antiviral Agents (DAAs)
20210 citationsauthor #13
Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded?
20213 citationsauthor #3
Antithrombotic Therapy and Liver Disease
20210 citationsauthor #2
Evaluation of procoagulant imbalance in Cushing’s syndrome after short- and long-term remission of disease
20217 citationsauthor #12
No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2
202110 citationsauthor #9
Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
202158 citationsauthor #3
Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET).
202142 citationsauthor #10
Diagnostic Challenges on the Laboratory Detection of Lupus Anticoagulant
202115 citationsauthor #1
Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH
202169 citationsauthor #6
Thrombopoietin receptor agonists before elective invasive procedures in cirrhotic patients with thrombocytopenia: ready to start?
20210 citationsauthor #3
Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge
20215 citationsauthor #1
General Aspects of Sepsis-Associated Coagulopathy
20211 citationsauthor #2
Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia
20218 citationsauthor #10
Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome
202126 citationsauthor #6
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection.
202114 citationsauthor #1
Assessment of hypercoagulability in patients with cushing syndrome before and after surgical cure
20200 citationsauthor #2
Is placental blood a reliable source for the evaluation of neonatal hemostasis at birth?
202017 citationsauthor #2
Factor VIII/protein C and not ADAMTS13/VWF:Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score
20200 citationsauthor #3
Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma
202017 citationsauthor #1
Procoagulant imbalance in patients with non-cirrhotic Chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis
20200 citationsauthor #10
Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: Harmonizing the manual tilt tube method
202011 citationsauthor #7
Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET
202022 citationsauthor #14
Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis
2020109 citationsauthor #1
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.
20208 citationsauthor #10
Coagulation abnormalities in patients with klinefelter syndrome compared to age-matched healthy controls: Cross-sectional assessment by thrombin generation test
20200 citationsauthor #13
Is umbilical cord blood a reliable source for the evaluation of neonatal hemostasis 1 at birth ? 2
20200 citationsauthor #2
COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).
2020309 citationsauthor #8
Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry
202013 citationsauthor #19
Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome
20208 citationsauthor #1
Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET).
202015 citationsauthor #13
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
202042 citationsauthor #10
Thromboelastography guided blood product transfusion in cirrhosis with coagulopathy: real saving or just less waste?
20202 citationsauthor #3
Usefulness of Thrombin Generation
20209 citationsauthor #1
Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis
20201,230 citationsauthor #9
Hemostatic alterations in COVID-19
202042 citationsauthor #13
Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis
2020310 citationsauthor #11
Thrombin generation: a global coagulation procedure to investigate hypo- and hyper-coagulability
202019 citationsauthor #1
Global coagulation tests to assess the value of the presurgical treatment in a patient with congenital factor XI deficiency and inhibitor
20200 citationsauthor #8
Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
20202 citationsauthor #2
Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study
20200 citationsauthor #7
Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini‐review
202024 citationsauthor #3
Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease
20204 citationsauthor #8
Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants.
20207 citationsauthor #3
Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis
201914 citationsauthor #11
Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban
20193 citationsauthor #1
Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A
201911 citationsauthor #7
Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.
201915 citationsauthor #1
Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study.
20194 citationsauthor #1
Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement
201929 citationsauthor #5
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study
201913 citationsauthor #50
Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: effect on conventional coagulation tests and thrombomodulin-modified thrombin generation.
201987 citationsauthor #3
Body mass index reduction improves the baseline procoagulant imbalance of obese subjects
201910 citationsauthor #1
Procoagulant imbalance in preterm neonates detected by thrombin generation procedures.
201912 citationsauthor #1
Thromboelastographic profiles of healthy very low birthweight infants serially during their first month
201924 citationsauthor #2
Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage
20190 citationsauthor #9
An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays
20196 citationsauthor #4
Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis.
2019310 citationsauthor #3
FRI-256-Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage
20190 citationsauthor #9
Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis.
20196 citationsauthor #2
Advances in the Treatment of Hemophilia: Implications for Laboratory Testing.
201931 citationsauthor #1
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
201998 citationsauthor #11
Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.
201862 citationsauthor #1
Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTem® device.
20184 citationsauthor #7
International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain
201823 citationsauthor #21
Requirement of a reference measurement system for the tissue factor-induced coagulation time and the international normalized ratio
20186 citationsauthor #5
The intra-assay reproducibility of thromboelastography in very low birth weight infants.
201812 citationsauthor #8
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START‐Laboratory Register
201811 citationsauthor #11
Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants
2018150 citationsauthor #11
Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban
201844 citationsauthor #4

TIMELINE

1974 0 citations

1980 8 citations

1981 2 citations

1982 65 citations

1983 7 citations

1984 17 citations

1985 48 citations

1986 38 citations

1987 119 citations

1988 46 citations

1989 43 citations

1990 6 citations

1991 90 citations

1992 275 citations

1993 182 citations

1994 402 citations

1995 32 citations

1996 64 citations

1997 137 citations

1998 241 citations

1999 174 citations

2000 81 citations

2001 363 citations

2002 379 citations

2003 489 citations

2004 554 citations

2005 924 citations

2006 1,252 citations

2007 928 citations

2008 736 citations

2009 2,614 citations

2010 1,249 citations

2011 2,411 citations

2012 435 citations

2013 1,114 citations

2014 572 citations

2015 355 citations

2016 1,578 citations

2017 486 citations

2018 370 citations

2019 673 citations

2020 2,220 citations

2021 397 citations

2022 166 citations

2023 37 citations

A. Tripodi

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT